Status:
TERMINATED
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Conditions:
Dengue
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model
Detailed Description
A Phase 1, double-blind, randomized, placebo-controlled study to assess the antiviral activity and safety of AT-752 in a Dengue Human Challenge Model
Eligibility Criteria
Inclusion
- Must agree to use protocol-specified methods of contraception
- Negative pregnancy test
- Willing to comply with the study requirements and to provide written informed consent
Exclusion
- Pregnant or breastfeeding
- Abuse of drugs
- Other clinically significant medical conditions
Key Trial Info
Start Date :
April 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05366439
Start Date
April 22 2022
End Date
March 16 2023
Last Update
April 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atea Study Site
Syracuse, New York, United States, 13215